Therapy Monitoring of EGFR-Positive Non–Small-Cell Lung Cancer Patients Using ddPCR Multiplex Assays
Open Access
- 1 April 2021
- journal article
- research article
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (4) , 495-505
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca (2017-02)
This publication has 19 references indexed in Scilit:
- Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCRThe Journal of Molecular Diagnostics, 2020
- EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCROncotarget, 2018
- Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to OsimertinibJAMA Oncology, 2018
- Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancerPLOS ONE, 2017
- EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancerOncotarget, 2017
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung CancerJAMA Oncology, 2016
- Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Oncotarget, 2016
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MNature Medicine, 2015
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAClinical Cancer Research, 2014